Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given a consensus recommendation of “Buy” by the twelve analysts that are currently covering the stock, Marketbeat reports. Twelve investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on the […]
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has been assigned a consensus recommendation of “Buy” from the twelve ratings firms that are covering the company, MarketBeat Ratings reports. Twelve investment analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued ratings on the stock […]
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.01), Briefing.com reports. During the same quarter in the prior year, the firm earned ($0.83) EPS. Rocket Pharmaceuticals Trading Down 1.5 % […]
StockNews.com upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) to a sell rating in a research note published on Saturday. A number of other brokerages have also issued reports on RCKT. Chardan Capital lowered their target price on shares of Rocket Pharmaceuticals from $63.00 to $61.00 in a research report on Friday, May 5th. […]
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) insider John Militello sold 573 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $19.03, for a total transaction of $10,904.19. Following the completion of the transaction, the insider now directly owns 7,129 shares in […]